| Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases. | |
| | |
MedLine Citation:
|
PMID: 1619019 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Twenty-nine patients with macroprolactinomas were treated by monthly intramuscular injections of the long-acting and repeatable form of bromocriptine (Parlodel-LAR) in doses ranging from 50-150 mg. They were divided into two groups: group I consisted of 22 patients who received Parlodel LAR before transsphenoidal adenomectomy; group II was composed of 7 patients with earlier neurosurgery and of 2 patients from group I not cured by transsphenoidal adenomectomy. Duration of therapy varied from 1-12 months, and a total of 104 injections was given. At nadir day, serum PRL levels were situated between less than 1% and 43% of pretreatment values. At day 28 after the first injection, serum PRL levels varied between less than 1% to 139% of initial values. No difference could be detected between the two groups regarding the percent of PRL inhibition. Long-term treatment with Parlodel-LAR resulted in a sustained inhibition of PRL secretion, except for 1 case. Resumption of menstrual cycles occurred in 4 out of 15 women and correction of hypogonadism in 4 out of 14 men. Amelioration of disturbed visual fields was recorded in 3 out of 8 patients. Diminution of the adenoma volume was radiologically documented in 14 out of 22 cases. Only few and mild side effects were recorded. One patient with partial adrenal deficiency suffered from a syncope, but this was prevented by hydrocortisone supplementation during the subsequent Parlodel-LAR administration. In conclusion, Parlodel-LAR proved effective in the treatment of macroprolactinomas, achieving rapid inhibition of PRL secretion, and in some patients amelioration of hypopituitarism, reduction in tumor size, and improvement in visual fields, and caused no serious side effects. It is a valuable preparation to surgery and can also be used in long-term medical therapy. |
| | |
Authors:
|
A Beckers; P Petrossians; R Abs; P Flandroy; T Stadnik; M de Longueville; I Lancranjan; A Stevenaert |
Related Documents
:
|
11124859 - Markers of tumor invasion are major predictive factors for the long-term outcome of cor... 1900379 - Pituitary function in thalassemic patients and the effect of chelation therapy. 14733699 - Long-term results of transperitoneal laparoscopic fenestration in the treatment of simp... 15497659 - Lessons from 6 years of gh receptor antagonist therapy for acromegaly. 9329359 - Effect of octreotide pretreatment on surgical outcome in acromegaly. 12532689 - Effect of the dose of oral hydrocortisone on growth rate during long-term treatment of ... 15729199 - Endoscopic therapy for gastroesophageal reflux disease: a systematic review. 21507029 - The efficacy of exclusive nutritional therapy in paediatric crohn's disease, comparing ... 1498319 - A multicenter prospective study on the treatment of chronic idiopathic thrombocytopenic... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The Journal of clinical endocrinology and metabolism Volume: 75 ISSN: 0021-972X ISO Abbreviation: J. Clin. Endocrinol. Metab. Publication Date: 1992 Jul |
Date Detail:
|
Created Date: 1992-07-31 Completed Date: 1992-07-31 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0375362 Medline TA: J Clin Endocrinol Metab Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 275-80 Citation Subset: AIM; IM |
Affiliation:
|
Department of Endocrinology, University of Liège, Belgium. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Bromocriptine / administration & dosage, adverse effects, therapeutic use* Delayed-Action Preparations Female Humans Injections, Intramuscular Male Middle Aged Nausea / chemically induced Pituitary Gland / physiology Pituitary Neoplasms / drug therapy* Prolactin / blood, secretion Prolactinoma / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Delayed-Action Preparations; 25614-03-3/Bromocriptine; 9002-62-4/Prolactin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Persistence of impaired insulin secretion in infant rhesus monkeys that had been hyperinsulinemic in...
Next Document: Growth hormone-releasing hormone-like messenger ribonucleic acid and immunoreactive peptide are pres...